Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00525876 · ClinicalTrials.gov registry record · NA
Non-Myeloablative Allogeneic Stem Cell Transplantation
A NA study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 49
- Enrollment target
NCT00525876: Completed NA study, sponsored by M.D. Anderson Cancer Center.
NCT00525876 is a NA study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 49 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00525876, a NA study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 49 participants
- Enrollment target
Study Summary
1. To determine the safety and efficacy of non-myeloablative allogeneic stem cell transplantation using rituximab, cyclophosphamide, fludarabine as a preparative regimen for patients with advanced or recurrent mantle cell lymphoma. 2. To determine factors associated with response and durable remission in patients receiving rituximab, cyclophosphamide, and fludarabine in preparation for allogeneic stem cell transplantation.
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG Alemtuzumab
- DRUG Rituximab
- PROCEDURE Allogeneic Stem Cell Infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2005-01 |
| Est. Completion | 2010-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00525876
The ClinicalTrials.gov registry entry for NCT00525876 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT00525876 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00525876 about?
NCT00525876 is a clinical study titled "Non-Myeloablative Allogeneic Stem Cell Transplantation". 1. To determine the safety and efficacy of non-myeloablative allogeneic stem cell transplantation using rituximab, cyclophosphamide, fludarabine as a preparative regimen for patients with advanced or recurrent mantle cell lymphoma. 2. To determine factors associated with response and durable remissi...
What is the current status of trial NCT00525876?
This trial is currently completed. It is a NA study. The enrollment target is 49 participants. The study started on 2005-01. Estimated completion is 2010-09.
What interventions are being tested in trial NCT00525876?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Alemtuzumab (DRUG), Rituximab (DRUG), Allogeneic Stem Cell Infusion (PROCEDURE).
Who is sponsoring clinical trial NCT00525876?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.